The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research. The University of Glasgow led study, published today in Nature Medicine, demonstrates the effectiveness of combining tigecycline with the drug imatinib – a tyrosine kinase inhibitor (TKI) and standard first-line treatment of patients...